New Drug Combo Unlocks PARP Inhibitors for Hard-to-Treat Ovarian Cancers

TEL AVIV, Israel & OSLO, Norway – July 08, 2026 – A promising new therapeutic strategy is emerging from the collaboration between BioLineRx and Hemispherian, potentially rewriting the rulebook for a significant portion of ovarian cancer patients. The companies today announced compelling preclinical data suggesting their novel drug, GLIX1, can make a powerful class of existing cancer drugs effective in tumors that were previously resistant, offering a beacon of hope for a large, underserved patient population.

The findings, derived from a patient-derived xenograft (PDX) model, demonstrate that combining GLIX1 with the PARP inhibitor olaparib creates a powerful synergistic effect against ovarian cancer. Remarkably, this combination therapy not only outperformed each drug used individually but also showed comparable tumor-shrinking efficacy to cisplatin, a cornerstone of chemotherapy, all while using lower doses of the targeted agents. This breakthrough could unlock the potential of PARP inhibitors for the 50% of ovarian cancer patients who currently see little to no benefit from them.

Cracking the Code of Resistance

Ovarian cancer remains the most lethal gynecologic malignancy in the United States, a grim reality driven by late-stage diagnosis and the frequent development of treatment resistance. Over the past decade, PARP inhibitors (PARPi) like olaparib have been a major advancement, particularly for patients whose tumors have a specific genetic vulnerability known as homologous recombination deficiency (HRD), often linked to mutations in genes like BRCA1 and BRCA2. These drugs work by exploiting a fatal flaw in the cancer cells' DNA repair machinery, a concept known as synthetic lethality.

However, this revolution has left a significant portion of patients behind. Approximately half of all high-grade serous ovarian cancers are considered "homologous recombination proficient" (HR-proficient), meaning their DNA repair pathways are intact, rendering PARP inhibitors largely ineffective. This creates a stark divide in treatment outcomes and leaves a substantial unmet need for new strategies that can overcome this intrinsic resistance. The challenge is compounded for patients who develop resistance to platinum-based chemotherapy, the standard first-line treatment, leaving them with very limited options.

"The central challenge in ovarian cancer today is expanding the benefit of targeted therapies beyond a genetically-defined subset of patients," commented an independent gynecologic oncologist not involved with the study. "Finding a way to sensitize HR-proficient tumors to PARP inhibitors would be a monumental step forward."

A Novel Mechanism of Synthetic Lethality

The innovation from BioLineRx and Hemispherian hinges on a new application of the synthetic lethality principle. Their drug, GLIX1, is a first-in-class small molecule that activates a pathway governed by the TET2 enzyme. In cancer cells, activating this pathway is designed to overwhelm their DNA repair capacity by inducing a cascade of single-strand DNA breaks.

This is where the synergy begins. While a healthy cell or an HR-proficient cancer cell can typically handle these breaks, the simultaneous administration of a PARP inhibitor blocks one of the key repair routes. The combination of GLIX1-induced damage and PARP-inhibited repair effectively creates a new synthetic lethal environment. It forces the HR-proficient cancer cell into a state of crisis it cannot escape, leading to programmed cell death. Essentially, GLIX1 makes previously resistant tumors vulnerable to the PARP inhibitor's mechanism of action.

The preclinical study provides strong in vivo validation for this theory. The combination arm demonstrated substantially better efficacy than either GLIX1 or olaparib monotherapy, even when the single drugs were given at their optimal doses. The fact that the low-dose combination matched the power of the chemotherapy benchmark, cisplatin, suggests a potentially more tolerable and highly effective future treatment regimen.

The Strategic Gambit by BioLineRx and Hemispherian

This development is a calculated move by the Israeli-Norwegian partnership. BioLineRx, a clinical-stage biopharma company, and Hemispherian, an oncology-focused innovator, are jointly advancing GLIX1 through a shared commitment to tackling difficult cancers. GLIX1 is already being evaluated in a Phase 1/2a clinical trial for glioblastoma, a notoriously aggressive brain cancer, demonstrating its ability to penetrate the blood-brain barrier—a valuable attribute for any systemic cancer therapy.

The strength of the new ovarian cancer data has prompted a swift strategic pivot. "GLIX1 has the potential to sensitize patients to PARP inhibitors as well as to potentially address the huge unmet need for patients with platinum-resistance," said Philip Serlin, Chief Executive Officer of BioLineRx, in the company's official statement. "Based on these highly encouraging data, we plan to include an ovarian cancer arm in the expansion part of our ongoing Phase 1/2a study."

This expansion could significantly de-risk the development program by exploring GLIX1's potential in a second major oncology indication. For investors, this move diversifies the asset's potential return. BioLineRx, which holds more cash than debt, is positioned to execute this expanded clinical strategy. A successful outcome could not only create a new standard of care but also dramatically expand the market for PARP inhibitors, a class of drugs that already generates billions in annual revenue, by unlocking a new, large patient segment.

From Bench to Bedside: The Path Forward

While the preclinical results are exceptionally encouraging, the journey from laboratory models to patient care is long and fraught with challenges. The patient-derived xenograft models are sophisticated, but they cannot fully replicate the complex tumor microenvironment and immune interactions within the human body.

The true test will come in the newly planned ovarian cancer cohort of the Phase 1/2a trial. This next stage will be critical for establishing the safety and tolerability of the GLIX1-olaparib combination in humans and for confirming that the powerful synergy seen in the lab translates into meaningful clinical benefit for patients. Researchers will also be keen to identify biomarkers that can predict which patients are most likely to respond, further refining the treatment approach.

"While promising, the transition from preclinical models to human trials is where many novel therapies face their biggest test," a leading drug development analyst noted. "We will be watching the safety and efficacy data from the planned clinical expansion very closely, as it represents a key inflection point for the GLIX1 program and a potential paradigm shift for a large group of cancer patients."